Pragmatic issues in biomarker evaluation for targeted therapies in cancer (Q38271031)

1 September 2017

1 reference

title

Pragmatic issues in biomarker evaluation for targeted therapies in cancer (English)

1 reference

1 September 2017

0 references

Josep Tabernero Caturla

5

1 reference

1 September 2017

6

Aimery de Gramont

0 references

author name string

Armand de Gramont

1

1 reference

1 September 2017

Sarah Watson

2

1 reference

1 September 2017

Lee M Ellis

3

1 reference

1 September 2017

Jordi Rodón

4

1 reference

1 September 2017

Stanley R Hamilton

7

1 reference

1 September 2017

language of work or name

English

0 references

publication date

25 November 2014

1 reference

Nature Reviews Clinical Oncology

1 September 2017

1 reference

1 September 2017

12

1 reference

1 September 2017

4

1 reference

1 September 2017

197-212

1 reference

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

1 September 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Trends in risks associated with new drug development: success rates for investigational drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Trial watch: Phase II failures: 2008-2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Phase III and submission failures: 2007–2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Fit-for-purpose method development and validation for successful biomarker measurement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Quantification of immunohistochemistry--issues concerning methods, utility and semiquantitative assessment I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Can a more selective application of antigen retrieval facilitate standardization in immunohistochemistry?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

A comparison of HER2/neu gene amplification and its protein overexpression between primary breast cancer and metastatic lymph nodes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Should liver metastases of breast cancer be biopsied to improve treatment choice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

HER-2/neu expression in primary and metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Molecular alterations between the primary breast cancer and the subsequent locoregional/metastatic tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Breast cancer subtypes and outcome after local and regional relapse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Stability of HER2-positive status in breast carcinoma: a comparison between primary and paired metastatic tumors with regard to the possible impact of intervening trastuzumab treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients:implications for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Stability of K-ras mutations throughout the natural history of human colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Molecular staging of colorectal cancer: K-ras mutation analysis of lymph nodes upstages Dukes B patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Molecular changes in the Ki-ras and APC genes in primary colorectal carcinoma and synchronous metastases compared with the findings in accompanying adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

A comparison of Direct sequencing, Pyrosequencing, High resolution melting analysis, TheraScreen DxS, and the K-ras StripAssay for detecting KRAS mutations in non small cell lung carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

K-ras point mutations in human colorectal carcinomas: relation to aneuploidy and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

The causes and consequences of genetic heterogeneity in cancer evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Influence of tumour micro-environment heterogeneity on therapeutic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Cell-free nucleic acids as biomarkers in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Amplification of whole tumor genomes and gene-by-gene mapping of genomic aberrations from limited sources of fresh-frozen and paraffin-embedded DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Integrating biomarkers in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Biomarkers and surrogate end points--the challenge of statistical validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Pre-analytic variables and phospho-specific antibodies: the Achilles heel of immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Evaluation of a standardized protocol for processing adrenal tumor samples: preparation for a European adrenal tumor bank.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Factors in tissue handling and processing that impact RNA obtained from formalin-fixed, paraffin-embedded tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

A high frequency of sequence alterations is due to formalin fixation of archival specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

An efficient procedure for protein extraction from formalin-fixed, paraffin-embedded tissues for reverse phase protein arrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Equivalence of protein inventories obtained from formalin-fixed paraffin-embedded and frozen tissue in multidimensional liquid chromatography-tandem mass spectrometry shotgun proteomic analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Microarray analysis of RNA extracted from formalin-fixed, paraffin-embedded and matched fresh-frozen ovarian adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Factors influencing the degradation of archival formalin-fixed paraffin-embedded tissue sections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Impact of ischemia and procurement conditions on gene expression in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Dynamic and modern: bringing the ethics of phase I trials up to date.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Quantification of immunohistochemistry--issues concerning methods, utility and semiquantitative assessment II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Standardization of HER2 testing: results of an international proficiency-testing ring study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

High-throughput droplet digital PCR system for absolute quantitation of DNA copy number

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Quantitative and sensitive detection of rare mutations using droplet-based microfluidics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Enabling personalized cancer medicine through analysis of gene-expression patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

A comparison of EGFR mutation testing methods in lung carcinoma: direct sequencing, real-time PCR and immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Expression of key oestrogen-regulated genes differs substantially across the menstrual cycle in oestrogen receptor-positive primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Ki67 measured after neoadjuvant chemotherapy for primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Discordance in early breast cancer for tumour grade, estrogen receptor, progesteron receptors and human epidermal receptor-2 status between core needle biopsy and surgical excisional primary tumour.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Low concordance of biomarkers in histopathological and cytological material from breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Delay to formalin fixation effect on breast biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

21 January 2018

Assessing EGFR mutations

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Molecular biomarker analyses using circulating tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

An intra- and interobserver reproducibility analysis of the Ki-67 proliferation marker assessment on core biopsies of breast cancer patients and its potential clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Are needs assessments cost effective in reducing distress among patients with cancer? A randomized controlled trial using the Distress Thermometer and Problem List

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Phase II study assessing lapatinib added to letrozole in patients with progressive disease under aromatase inhibitor in metastatic breast cancer-Study BES 06.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Ceritinib in ALK-rearranged non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Ceritinib for treatment of ALK-rearranged advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Biopsy of liver metastasis for women with breast cancer: Impact on survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Recommendations for Improved Standardization of Immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Parallel anticancer drug development and molecular stratification to qualify predictive biomarkers: dealing with obstacles hindering progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Change of HER-2/neu status in a subset of distant metastases from breast carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

c-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

HER2 status in a population-derived breast cancer cohort: discordances during tumor progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Heterogeneous distribution of K-ras mutations in primary colon carcinomas: implications for EGFR-directed therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Improving the limit of detection for Sanger sequencing: A comparison of methodologies for KRAS variant detection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

DNA damage caused by common cytological fixatives

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Gene expression analysis of normal and colorectal cancer tissue samples from fresh frozen and matched formalin-fixed, paraffin-embedded (FFPE) specimens after manual and automated RNA isolation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

HER2 status and benefit from adjuvant trastuzumab in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.202

Tissue handling for genome-wide expression analysis: a review of the issues, evidence, and opportunities

31 March 2020

1 reference

12 December 2020

Interlaboratory comparison of immunohistochemical testing for HER2: results of the 2004 and 2005 College of American Pathologists HER2 Immunohistochemistry Tissue Microarray Survey

1 reference

12 December 2020

Impact of freeze-thaw cycles and storage time on plasma samples used in mass spectrometry based biomarker discovery projects

1 reference

12 December 2020

Sensitive detection of K-ras mutations augments diagnosis of colorectal cancer metastases in the liver.

1 reference

12 December 2020

Epidermal growth factor receptor changes during breast cancer metastasis.

1 reference

12 December 2020

[Technical considerations for KRAS testing in colorectal cancer. The biologist's point of view].

1 reference

12 December 2020

Concordant analysis of KRAS status in primary colon carcinoma and matched metastasis

1 reference

12 December 2020

HER-2/neu Status in Breast Cancer Metastases to the Central Nervous System

1 reference

12 December 2020

Effects of preanalytical variables on the detection of proteins by immunohistochemistry in formalin-fixed, paraffin-embedded tissue

1 reference

12 December 2020

Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements

1 reference

12 December 2020

10.1038/NRCLINONC.2014.202

Identifiers

DOI

1 reference

1 September 2017

1 reference